Once a multi­bil­lion dol­lar com­pa­ny, Ova­Science ends a pen­ny­s­tock ve­hi­cle for Mil­len­do's re­verse merg­er

An am­bi­tious fer­til­i­ty com­pa­ny plagued by a se­ries of dis­ap­point­ments is play­ing out its fi­nal act — serv­ing as a ve­hi­cle for an­oth­er ven­ture’s suc­cess. Ova­Science, once val­ued at $1.8 bil­lion for its idea to help old­er women ex­tend their re­pro­duc­tive years, is merg­ing with Ann Ar­bor’s Mil­len­do Ther­a­peu­tics.

The re­verse merg­er is a way for Mil­len­do to back its way on­to the Nas­daq mar­ket, as Ova­Science is al­ready list­ed as $OVAS. Us­ing a near­ly-de­funct pub­lic com­pa­ny as a ve­hi­cle is a fair­ly com­mon way to gain ac­cess to the pub­lic mar­kets with­out go­ing on a lengthy road­show and putting to­geth­er your own IPO. Af­ter the merg­er is wrapped up, the com­bined com­pa­ny will be called Mil­len­do Ther­a­peu­tics, of course, and the new tick­er sym­bol will be $ML­ND.

Ju­lia Owens

A group of in­vestors has come to­geth­er to back Mil­len­do, com­mit­ting $30 mil­lion for af­ter the merg­er is com­plete. The mon­ey comes from New En­ter­prise As­so­ci­ates, Fra­zier Health­care Part­ners, and Roche Ven­ture Fund, among oth­ers. The new mon­ey will set up Mil­len­do to push for­ward two pro­grams: ATR-101, in Phase IIb tri­als for con­gen­i­tal adren­al hy­per­pla­sia, a rare en­docrine dis­ease; and a brand new drug to its pipeline called liv­o­le­tide. The lat­ter is a Phase II pro­gram ac­quired from French biotech Al­izé Phar­ma SAS last year. The med is meant to treat a rare ge­net­ic dis­ease called Prad­er-Willi Syn­drome (the most com­mon form of ge­net­ic obe­si­ty). That pro­gram is planned to en­ter Phase IIb/III tri­als in the first quar­ter of 2019.

“We are ex­cit­ed about the op­por­tu­ni­ties cre­at­ed by this merg­er, as it po­si­tions us to be­come a leader in rare en­docrine dis­eases with the fund­ing need­ed to pur­sue the po­ten­tial ap­proval and com­mer­cial­iza­tion of our first-in-class pro­grams,” said Ju­lia Owens, pres­i­dent and CEO of Mil­len­do, in a state­ment.

It’s good news for Mil­len­do, but a sad end for Ova­Science. Ova­Science was found­ed sev­en years ago around the dog­ma-chal­leng­ing claim by a sci­en­tist now at North­east­ern Uni­ver­si­ty that he had dis­cov­ered “egg pre­cur­sor” cells in hu­man ovaries that could gen­er­ate new, young eggs for old­er women, po­ten­tial­ly ex­tend­ing re­pro­duc­tive years. Ova­Science’s founders in­clud­ed Boston/Cam­bridge big shots like Rich Aldrich, Michelle Dipp, David Sin­clair and Christophe West­phal.

Ex­tend­ing fer­til­i­ty years was the long goal, but the com­pa­ny’s first lead prod­uct, called Aug­ment, was meant to boost a woman’s chance of preg­nan­cy dur­ing IVF treat­ment. The up­take for that ser­vice was painstak­ing­ly slow, and the com­pa­ny’s stock slow­ly de­clined over the years. One day a multi­bil­lion dol­lar com­pa­ny, the next it’s firm­ly a pen­ny­s­tock.

Hal Barron, GSK

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

Just ahead of GlaxoSmithKline’s Q2 update on Wednesday, science chief Hal Barron is making the rounds to talk up the pharma giant’s late-stage strategy as the top execs continue to woo back a deeply skeptical investor group while pushing through a whole new R&D culture.

And that’s not easy, Barron is quick to note. He told the Financial Times:

I think that culture, to some extent, is as hard, in fact even harder, than doing the science.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Aca­dia is mak­ing the best of it, but their lat­est PhI­II Nu­plazid study is a bust

Acadia’s late-stage program to widen the commercial prospects for Nuplazid has hit a wall. The biotech reported that their Phase III ENHANCE trial flat failed. And while they $ACAD did their best to cherry pick positive data wherever they can be found, this is a clear setback for the biotech.

With close to 400 patients enrolled, researchers said the drug flunked the primary endpoint as an adjunctive therapy for patients with an inadequate response to antipsychotic therapy. The p-value was an ugly 0.0940 on the Positive and Negative Syndrome Scale, which the company called out as a positive trend.

Their shares slid 12% on the news, good for a $426 million hit on a $3.7 billion market cap at close.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

The nonprofit Bioethics International has come out with their latest scorecard on data transparency among the big biopharmas in the industry — flagging a few standouts while spotlighting some laggards who are continuing to underperform.

Now in its third year, the nonprofit created a new set of standards with Yale School of Medicine and Stanford Law School to evaluate the track record on trial registration, results reporting, publication and data-sharing practice.

Busy Gilead crew throws strug­gling biotech a life­line, with some cash up­front and hun­dreds of mil­lions in biobucks for HIV deal

Durect $DRRX got a badly needed shot in the arm Monday morning as Gilead’s busy BD team lined up access to its extended-release platform tech for HIV and hepatitis B.

Gilead, a leader in the HIV sector, is paying a modest $25 million in cash for the right to jump on the platform at Durect, which has been using its technology to come up with an extended-release version of bupivacaine. The FDA rejected that in 2014, but Durect has been working on a comeback.

In­tec blitzed by PhI­II flop as lead pro­gram fails to beat Mer­ck­'s stan­dard com­bo for Parkin­son’s

Intec Pharma’s $NTEC lead drug slammed into a brick wall Monday morning. The small-cap Israeli biotech reported that its lead program — coming off a platform designed to produce a safer, more effective oral drug for Parkinson’s — failed the Phase III at the primary endpoint.

Researchers at Intec, which has already seen its share price collapse over the past few months, says that its Accordion Pill-Carbidopa/Levodopa failed to prove superior to Sinemet in reducing daily ‘off’ time. 

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

Whoever is taking Otezla off Bristol-Myers Squibb’s hands will have one more revenue stream to boast.

The drug — a rising star in Celgene’s pipeline that generated global sales of $1.6 billion last year — is now OK’d to treat oral ulcers associated with Behçet’s disease, a common symptom for a rare inflammatory disorder. This marks the third FDA approval for the PDE4 inhibitor since 2014, when it was greenlighted for plaque psoriasis and psoriatic arthritis.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric (Biohaven)

In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

Biohaven is at risk of making a habit of disappointing its investors.

Late Friday the biotech $BHVN reported that the FDA had rejected its application for riluzole, an old drug that they had made over into a sublingual formulation that dissolves under the tongue. According to Biohaven, the FDA had a problem with the active ingredient used in a bioequivalence study back in 2017, which they got from the Canadian drugmaker Apotex.

Apotex, though, has been a disaster ground. The manufacturer voluntarily yanked the ANDAs on 31 drugs — in late 2017 — after the FDA came across serious manufacturing deficiencies at their plants in India. A few days ago, the FDA made it official.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.